UBS Downgrades Biohaven on Pipeline Setbacks
UBS cuts Biohaven to Neutral from Buy, lowering the price target to $11 due to multiple R&D and regulatory setbacks and rising competition in its Kv7 program.
Already have an account? Sign in.